Company: STAA
Filing Date: 2025-10-23
Form Type: DEFA14A
Source: 0001193125-25-248798
Chunk: 5

Company: STAAR SURGICAL CO
Filing Date: 2025-10-23
Form: DEFA14A
Chunk 5
---
 the global leader in eye care
dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer Lens (ICL), today announced that STAAR and Alcon have
agreed to adjourn STAAR’s Special Meeting of Stockholders (the “Special Meeting”) scheduled for October 23, 2025, in connection with STAAR’s merger agreement with Alcon. No other business will be conducted at the Special
Meeting.

STAAR is adjourning the Special Meeting until 8:30 a.m. Pacific Time on November 6, 2025. The record date for STAAR stockholders eligible
to vote at the Special Meeting remains the close of business on September 12, 2025.

Stockholders with questions about voting their shares should
contact STAAR’s proxy solicitor, Innisfree M&A Incorporated, toll-free at +1 877-750-8233. Banks and brokerage firms, please call +1 212-750-5833.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to
enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

About STAAR Surgical

STAAR Surgical (NASDAQ: STAA) is
the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR
has been designing, developing, manufacturing, and marketing advanced Implantable Collamer Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are
clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL product line provides visual freedom
through a quick, minimally invasive procedure. STAAR has sold more than